Loading cancer entity…
Loading cancer entity…
Clinical trials
74 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04462406 | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | active not recruiting | Phase 2 | 150 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | recruiting | Phase 2 | 112 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00937937 | Dinaciclib in Treating Patients With Stage IV Melanoma | active not recruiting | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05546827 | Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07400302 | Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery | recruiting | Phase 2 | 220 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,301 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT04318717 | Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma | recruiting | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07600476 | A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors | recruiting | Phase 1 | 21 | Kupando GmbHINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03698019 | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | active not recruiting | Phase 2 | 313 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07230613 | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma(NEOREM-NEO-1) | recruiting | Phase 2 | 50 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06424626 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | enrolling by invitation | Phase 1 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07215988 | Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study | recruiting | — | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07662694 | CLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma(CLASSIFY-OMM) | not yet recruiting | — | 1,100 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06319196 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma(ClearMe) | recruiting | Phase 2 | 54 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06999980 | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)(Neo IRENIE) | recruiting | Phase 2 | 494 | Melanoma Institute AustraliaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07347444 | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07336979 | Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07236528 | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | recruiting | Phase 2 | 99 | Emory UniversityOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03241186 | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | active not recruiting | Phase 2 | 36 | Robert R. McWilliams, MDOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04622566 | Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | not yet recruiting | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 13, 2020 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials